Bajaj Healthcare Limited — Updates, 28-07-2025: Press Release

Bajaj Healthcare delivered a strong Q1 FY26, with revenue rising 12.5% YoY to ₹148.84 Cr and profit surging 66% to ₹11.83 Cr. API exports showed robust 68.4% growth, and formulations grew 41.1%. The company is strategically realigning from domestic API due to pricing pressures towards value-added exports, with export contribution now 35%. Key European approvals received, enabling CDMO validation batch supplies. Their CNS portfolio advances: Cenobamate received positive feedback for Phase III trials, and Magtein® commercial launch is set for Q3.